Rising Cases of Jamestown Canyon Virus Present a Public Health Hazard

Changing climate patterns and the expansion of mosquito habitats are creating conditions that support the emergence of arboviruses in temperate regions. One such virus is Jamestown Canyon virus (JCV), which primarily circulates in the United States and Canada. JCV remains genetically stable, with closely related strains such as Inkoo virus identified in Europe. Antibodies to the virus have also been detected in wildlife across other temperate areas of North America.

JCV Transmission Driven by Mosquito-Ungulate Cycle with Rising Risk from Expanding Vector Ranges 

JCV is a California serogroup virus within the genus Orthobunyavirus and family Peribunyaviridae. It is transmitted primarily through the bites of infected mosquitoes, particularly species in the Aedes and Ochlerotatus genera, as well as some Culex mosquitoes.

In the United States, white-tailed deer serve as the main amplifying hosts. However, antibodies and infections have also been found in other ungulates such as mule deer, moose, elk, caribou, bison, and pronghorn, suggesting broader ecological reservoirs. JCV can also infect domestic animals like horses and goats, though their role in sustaining transmission remains uncertain.

The virus circulates in a mosquito-ungulate cycle. Mosquitoes acquire the virus while feeding on viremic animals, and may transmit it to humans or other mammals through subsequent bites. Humans typically have low viremia levels and are considered dead-end hosts. There is no evidence of direct human-to-human transmission, though rare cases via blood transfusion or organ transplantation are theoretically possible.

Experimental research indicates that Aedes aegypti mosquitoes are highly competent JCV vectors, with the virus quickly reaching their saliva after feeding. While Wolbachia-infected mosquitoes moderately block JCV transmission, this effect is weaker than with positive-sense viruses. As mosquito habitats expand due to climate change, the risk of JCV infections may rise, particularly between April and September when mosquito activity peaks.

Rising JCV Cases in North America Linked to Improved Detection and Expanding Mosquito Habitats

The virus was first isolated in 1961 from Culiseta inornata mosquitoes in Jamestown, Colorado. Since then, human cases have been sporadically reported. However, JCV has expanded into a more widespread arboviral concern throughout the United States and parts of Canada. Higher infection rates have been documented in northern states such as Minnesota and Wisconsin. Genetic analyses show minimal variation among strains, even those collected decades apart and from distant regions, indicating evolutionary stability.

Data from the U.S. Centers for Disease Control and Prevention (CDC) show a notable increase in reported cases over time. Prior to 2013, only about two cases were reported annually. Following the implementation of routine testing, reports rose to nearly 30 per year. Many cases involve neuroinvasive disease, with prolonged illness common among adults, although fatalities remain rare.

While better diagnostic tools have likely contributed to the rise in reported cases, environmental and ecological changes also play a key role. Climate change has expanded mosquito habitats, and increased human-wildlife interactions may be enhancing viral transmission opportunities.

No Approved Therapies for JCV, Prevention Relies on Vector Control and Protective Measures

There is currently no approved antiviral treatment for JCV. Instead, medical care focuses on supportive treatment to relieve symptoms. For mild cases, rest, hydration, and over-the-counter pain relievers are typically sufficient. However, in more serious cases, particularly those involving neurological complications such as meningitis or encephalitis, hospitalization may be required. Patients may need intravenous fluids, anti-nausea medications, and monitoring for complications like seizures or elevated intracranial pressure. In rare but severe cases, intensive care support may become necessary. Although vaccine research is ongoing, no preventive or therapeutic vaccines have been licensed.

Given the absence of specific treatments or vaccines, prevention relies heavily on minimizing mosquito exposure. To reduce individual risk, health authorities recommend using EPA-approved insect repellents, wearing long sleeves and pants, treating clothing with permethrin, and avoiding outdoor activities during peak mosquito activity periods, particularly at dawn and dusk. These personal protection measures are especially important in regions where JCV is known to circulate.

At the community level, prevention efforts aim to control mosquito populations and raise public awareness. This includes eliminating standing water, applying larvicides, and managing outdoor environments to reduce breeding habitats. In addition, public health campaigns play a vital role in educating communities about mosquito-borne risks. Early detection systems also help track mosquito activity and detect outbreaks.

Author

Denisse Sandoval